C HEALTH GP (08225) announced that it recently held the "AI-RWS Real World Research Summit" in Shanghai, launching over ten AI-driven Real World Studies (AI-RWS) projects targeting two major psychiatric and neurological diseases: adolescent mental disorders in China and behavioral and psychological symptoms of dementia (BPSD). This marks a crucial step in the company's strategic positioning in the "AI+Clinical Research" track in Hong Kong stocks, further consolidating its industry-leading position.

**Academic and Research Framework**

The summit brought together 40 leading domestic experts in pediatrics, adolescent psychiatry, and geriatric cognitive disorders. Drawing from Stanford University and Mayo Clinic methodologies and referencing the latest evidence-based guidelines from JAMA Psychiatry 2024, the company has established a comprehensive closed-loop research system encompassing "AI intelligent classification - personalized treatment pathway optimization - dynamic efficacy and safety prediction - early warning for relapse risk."

This system integrates NLP and deep learning technologies with multi-dimensional real-world data to provide high-level real-world evidence (RWE) tailored to Chinese population characteristics for both disease categories.

**Core Track Positioning and Key Products**

1. **Hundred-Billion Adolescent Mental Disorder Track**: Targeting China's patient population exceeding 30 million, the company launched AI-RWS cohort studies covering over 30 institutions across 15 cities nationwide, involving more than 10,000 patients. Simultaneously conducting real-world research on Xixin adolescent treatments, exploring combination and sequential therapy for comorbidities involving the Xixin drug portfolio including Xixin A, Xixin Ai, Xixin Li, Xixin An, Xixin She, and Xixin Le.

Through proprietary AI algorithms, three major enterprise innovation services are achieved: optimizing pediatric psychiatric research protocols, conducting new drug portfolio comorbidity studies, and enabling disease progression prediction. Results will support clinical practice guideline iterations and medical insurance policy formulation.

2. **Trillion-Dollar Dementia and BPSD Track**: Launching the "Stellar Plan" to build China's largest and longest follow-up BPSD real-world database, planning to include 100,000 patients within five years. The focus includes non-pharmacological interventions and combination therapy research, providing crucial data for innovative drug registration and post-marketing safety re-evaluation.

- **Core Clinical Research Focus**: The company has obtained exclusive clinical research experimental rights and real-world clinical research exclusive rights for Xien Ka micro-tablets nano-microparticles and Xien Mei flash tablets in China.

- **Core Product**: Xien Ka micro-tablets nano-microparticles, a globally exclusive formulation covered by national medical insurance, represents a Grade A recommended product with Level 1 evidence for treating mild-to-moderate dementia. Utilizing VSMART patented technology, it solves swallowing difficulties, can be mixed with liquid foods, avoids gastrointestinal reactions, and demonstrates superior therapeutic effects for patients with comorbid psychiatric and Parkinson's disorders compared to other similar products.

**Commercialization Pathway and Future Outlook**

The company adopts a diversified funding model combining "joint construction with research hospitals + pharmaceutical enterprise commissioning + government special projects + insurance co-payment," with individual project values ranging from tens of millions to hundreds of millions of yuan. Leveraging platforms such as Hainan Boao and Hengqin, the company can reduce Phase IV clinical research time for partners by over 30%. Research outcomes and core product advantages align with relevant national health commission strategies, providing policy dividend advantages.

Looking ahead, the company will focus on AI-RWS research and intelligent physician agent development, with core positioning in three major areas: Xixin psychiatric brand, Xien neurological brand, and Baimin allergic reaction brand, aiming to become a global leader in this field. The company accelerates transformation toward AI-driven clinical research services to create superior value returns for shareholders.